Saluda Medical

OverviewSuggest Edit

Saluda Medical is a global medical device company focused on developing evoked compound action potential (ECAP) devices such as Evoke for the neuromodulation industry. It measures the spinal cord’s response to stimulation, adjusts on every pulse to optimize activation within the patient’s therapeutic window, and maintains long-term results through ECAP control. 

TypePrivate
Founded2011
HQArtarmon, AU
Websitesaludamedical.com
Employee Ratings4.4

Latest Updates

Employees (est.) (Oct 2021)209(-2%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Saluda Medical

John Parker

John Parker

Founder & CEO
Chris Beare

Chris Beare

Chairman and Independent Director
Greg Plamondon

Greg Plamondon

Chief Financial Officer
Lisa Emerson

Lisa Emerson

Senior Vice President, Regulatory Affairs and Quality Assurance
Jim Schuermann

Jim Schuermann

President
Dean Karantonis

Dean Karantonis

Vice President, Therapy Development
Show more

Saluda Medical Office Locations

Saluda Medical has offices in Artarmon, Minneapolis and Harrogate
Artarmon, AU (HQ)
Ground Floor, 407 Pacific Hwy
Harrogate, GB
9 Hornbeam Square S
Minneapolis, MN, US
9401 James Ave S #132
Show all (3)

Saluda Medical Financials and Metrics

Summary Metrics

Founding Date

2011

Saluda Medical total Funding

$125 m

Saluda Medical latest funding size

$75 m

Time since last funding

2 years ago

Saluda Medical investors

Saluda Medical's latest funding round in June 2019 was reported to be $75 m. In total, Saluda Medical has raised $125 m
Show all financial metrics

Saluda Medical Online and Social Media Presence

Embed Graph

Saluda Medical News and Updates

Saluda Medical Announces Executive Leadership Changes

ARTARMON, Australia, Feb. 12, 2021 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), the market leader in the development of novel closed-loop spinal cord stimulation (SCS) for the treatment of chronic pain, today announced the appointment of Jim Schuermann as President &...

Saluda Medical Results of U.S. Evoke Pivotal Study through 12 Months Published in The Lancet Neurology

ARTARMON , Australia, Dec. 20, 2019 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announced The Lancet Neurology journal published results from the U.S. Pivotal Study demonstrating its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System provided...

Saluda Medical Announces European Commercial Launch of Evoke®, the First and Only ECAP-Controlled, Closed-Loop SCS System for Chronic Pain Relief

ARTARMON, Australia, Sept. 16, 2019 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announced the award of CE Mark and the European commercial launch of the Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for the treatment of chronic pain. The...

Saluda Medical Blogs

Saluda Medical Announces Publication of 24-Month Spinal Cord Stimulation Results with the Evoke® System

Results show ~90% overall back and leg responder rate, ~68% high responder rate, and zero explants due to loss of efficacy ~83% of patients reduced or eliminated opioid use Need for patient re-programming visits nearly eliminated after 12 months Represents the first peer reviewed SCS study to show r…

Saluda Medical Partners with Health Awareness on the 2021 Managing Pain Campaign

Read for commentary from key thought leaders and industry voices raising awareness for those living with pain and the management options available. The post Saluda Medical Partners with Health Awareness on the 2021 Managing Pain Campaign appeared first on Saluda Medical.

Saluda Medical Announces Highlights from 2021 North American Neuromodulation Society (NANS) Meeting

Growing Clinical Evidence Base for Evoke® Closed-Loop SCS System  Artarmon, Australia – January 20, 2021 – Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of closed-loop spinal cord stimulation for the treatment of chronic pain, announced scientific highlights fro…

Saluda Medical Announces Scientific Presentations at 2021 North American Neuromodulation Society (NANS) Meeting

Artarmon, Australia – January 7, 2021 – Saluda Medical Pty Limited (“Saluda Medical”), developer of the Evoke®Closed-Loop Spinal Cord Stimulation (SCS) System for the treatment of chronic pain, announced the scientific presentation schedule at the 2021 North American Neuromodulation Society Virtual …

NICE Publishes Briefing on Saluda’s Evoke Closed-Loop Spinal Cord Stimulation (SCS) System

Artarmon, Australia – December 22, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) announced today that the UK's National Institute for Health and Care Excellence (NICE) issued a Medtech Innovation Briefing (MIB) titled “Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic…

Saluda Medical Frequently Asked Questions

  • When was Saluda Medical founded?

    Saluda Medical was founded in 2011.

  • Who are Saluda Medical key executives?

    Saluda Medical's key executives are John Parker, Chris Beare and Greg Plamondon.

  • How many employees does Saluda Medical have?

    Saluda Medical has 209 employees.

  • Who are Saluda Medical competitors?

    Competitors of Saluda Medical include Nevro Corp., Terumo Aortic and Breas Medical.

  • Where is Saluda Medical headquarters?

    Saluda Medical headquarters is located at Ground Floor, 407 Pacific Hwy, Artarmon.

  • Where are Saluda Medical offices?

    Saluda Medical has offices in Artarmon, Minneapolis and Harrogate.

  • How many offices does Saluda Medical have?

    Saluda Medical has 3 offices.